This is a Phase 2, single arm, single center study designed to evaluate the safety and
tolerability of radiofrequency ablation combined with PD-1 monoclonal antibody in patients
with hepatocellular carcinoma(HCC), with the secondary study objective to preliminarily
evaluate the efficacy of radiofrequency ablation combined with PD-1 monoclonal antibody in
patients with HCC and the exploratory study objective to evaluate the effect of ablation
combined with PD-1 monoclonal antibody on immune function and hepatitis virus infection
status in patients with HCC. This study will be divided into two stages, and the first stage
is to enroll 6 patients for dose-limited toxicity (DLT) observation. If DLT appeared in < 2
patients, the second stage was entered and the other 24 patients were further enrolled.